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Abstract
Recent decades have seen exciting developments in the field of movement  disorders. These 
include identification of rare clinical syndromes and use of technological advances to 
understand their pathogenesis. Three such disorders are discussed here. The  description 
of the Uner Tan syndrome from Turkey and surrounding regions provoked research 
into the controversial field of genetically induced devolution. Such cases with few addi‐
tional findings have now been described from India. Sepiapterin reductase  deficiency 
is a rare treatable autosomal recessive form of dopa responsive dystonia. Indian litera‐
ture has recently added five confirmed cases to the international database. Such cases 
are eminently treatable. Successful application of modern technology in understanding 
the pathogenesis of progressive neurodegenerative disorder has been highlighted in the 
 section on hereditary spastic paraplegias. Hitherto undescribed subcellular organelle 
transport defects and their potential rectification with known drugs have been demon‐
strated raising hopes for their cure.
Keywords: movement disorders, Uner Tan syndrome, neurogenetics, sepiapterin 
reductase deficiency, hereditary spastic paraplegia, stem cell modelling of HSP
1. Introduction
Movement disorders is a relatively young but fast growing sub‐speciality of neurology. Recent 
developments in the clinical, genetics and treatment aspects of this group of disorders are 
exciting. The nature of movement disorders seen in India differ from the western cases. The 
vast population of the country where consanguineous marriages are still prevalent is a source 
of large number of rare movement disorders. Modern technology including whole genome 
sequencing has promoted in‐depth understanding of such cases. In addition, such rare disor‐
ders can lead to physical disability especially in children when they remain undiagnosed and 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
untreated. This paper highlights selected Indian contributions to such  developments with 
an intention to increase awareness about such rare disorders. Some of them are potentially 
 treatable. The topics discussed here include Uner Tan syndrome, sepiapterin reductase defi‐
ciency and hereditary spastic paraplegia.
2. Uner Tan syndrome
In the year 2005, Uner Tan from Turkey discovered and described an autosomal recessive 
genetic syndrome, at present, recognized as Uner Tan syndrome (UTS), which composed of 
habitual quadrupedalism, impaired intelligence, primitive language and no conscious expe‐
rience [1]. The cases described by him had quadrupedal locomotion (Q/L) using two palms 
and two feet with extended legs. Some of them later developed bipedal locomotion (B/L) 
although Q/L remained the preferred mode of locomotion. Recently he has described similar 
cases  presenting with infantile hypotonia which disappeared by adolescence to be replaced 
by quadrupedal locomotion [2]. The cases without infantile hypotonia are now identified 
as UTS Type I and those associated with infantile hypotonia are identified as UTS Type II 
cases. Considering the unusual psychomotor behaviour of these cases, resembling that of 
sub‐human primates, Uner Tan proposed the theory of ‘genetically induced devolution’ to 
explain the genesis of this syndrome. This theory has been questioned by other researchers 
[3]. This chapter documents two new families of UTS from India. Additional features of dys‐
tonia, which appear with their bipedal locomotion, are highlighted.
2.1. Indian cases of UTS
The present chapter describes clinical and radiological findings in three cases of UTS belong‐
ing to two Indian families [4] (Figure 1). Both of these families resided in Mantur, a small vil‐
lage belonging to Belagavi district in the state of Karnataka. The village is close to semi urban 
cities with exposure to modern lifestyle practices. Family A had one female case, whereas 
Family B had two male cases affected by the syndrome. Autosomal recessive type of trans‐
mission was identified in each of the families. There was no history of birth asphyxia, trauma 
or encephalitis in any of the cases. Haematological and biochemical tests, including serum 
parathormone, vitamin D3, B‐12, copper and ceruloplasmin levels, were measured and found 
to be within normal limits. The VLDL receptor gene was negative in all the cases. For sake of 
brevity, the girl belonging to Family A is designated as Case A‐1 and the brothers belonging 
to Family B are designated as Case B‐1 (elder) and Case B‐2 (younger), respectively.
2.1.1. Case A‐1
This girl who was born of post‐term pregnancy as a large baby had remained floppy until the 
age of 5 years. She developed Q/L at the age of 6 years and B/L at the age of 11 years. She had 
features of severe mental retardation with a MMSE score of 0/30. Speech was absent but she 
repeatedly mumbled a meaningless word. She responded to few commonly used non‐verbal 
commands. Self‐care was poor. Most often she moved using Q/L, but at times attempted 
walking with a wide‐based ataxic bipedal gait. She suffered sleep onset epileptic seizures 
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from the age of 18 months, which were partly controlled with phenobarbitone. MRI of the 
brain revealed moderately severe hypoplasia of the cerebellum including the vermis along 
with mild cerebral cortical thinning.
2.1.2. Case B‐1
This 35‐year‐old male who was born of full‐term normal home delivery had no infantile hypo‐
tonia. Features of severe mental retardation were present with no speech but he was able to 
follow few non‐verbal commands. MMSE score was 0/30 and self‐care was poor. He exhibited 
severe autistic behaviour avoiding eye to eye contact with others. He used only Q/L which had 
appeared at the age of 7 years (Figure 2). He never attempted B/L. He could be made to stand 
with support for few seconds using a wide base support. He suffered rare episodes of general‐
ized tonic‐clonic seizures which remained untreated. Neuroimaging was not possible in him.
Figure 1. The top section of the figure shows the genogram of Families A and B. The lower section of the figure shows 
MRI/CT brain images of patients A‐1 and B‐2, respectively. The images reveal the presence of cerebellar atrophy.
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2.1.3. Case B‐2
This 30‐year‐old younger brother of Case B‐1 and born of normal home delivery had evidence 
of severe mental retardation with no speech and MMSE score of 0/30. He exhibited autistic 
behaviour shunning crowds and often strayed away silently. He had developed Q/L at the 
age of 7 years and B/L at the age of 25 years. His bipedal gait was wide‐based and short‐stride 
but not ataxic. He had camptocormia and almost continuous dystonia abductor posturing of 
his right arm during bipedal locomotion. Presently, he prefers to move bipedally for most of 
the time. A CT scan of the head revealed evidence of cerebellar hypoplasia.
2.1.4. Discussion
The diagnosis of UTS was made in these cases based on the presence of the cardinal features 
of the syndrome as mentioned above.
Most cases reported by Uner Tan resided in remote villages of Turkey having poor 
 communication with the outer world. He proposed that their alienation from outside world, 
Figure 2. The figure is a still photography of Case B‐1 showing the quadrupedal locomotion. Note the diagonal 
sequencing of the limbs and the extension of the lower extremities at the knee.
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low socio‐economic status, poor nutrition and poor parental care may be contributing to the 
causation of the syndrome [1]. In contrast although our cases resided in a village, they were 
exposed to modern lifestyle practices in view of close proximity to urban settings. These sibs 
lived protected as members of ‘nuclear families’, a concept still prevalent in rural India.
In addition to the cardinal features of the syndrome, these patients had (i) microcephaly with 
facial dysmorphism, (ii) restrictive repetitive behaviours and stereotypies and (iii) poor social 
interaction. Head circumference in relation to body height measurements mentioned in the 
table indicates the presence of mild microcephaly in all the cases. While Case A‐1 had the 
feature of repetitive mumbling of a meaningless word, a form of verbal stereotypy, Case B‐1 
and Case B‐2 had extremely shy behaviour avoiding eye to eye contact, social interaction 
and communication. Dystonic limb posturing was present in cases 2 and 3 during attempted 
bipedal locomotion.
The pathophysiology of habitual quadrupedalism is unclear. The role of central pattern gen‐
erators (CPG) present in the cervical and the lumbosacral spinal segments has been discussed 
in this regard. Reorganization and adaptation of CPG networks is possibly involved in the 
appearance of human quadrupedal locomotion [5]. Considering the complex balance mecha‐
nisms needed for a well‐balanced bipedal locomotion, walking on all the four is much easier 
since the overall base of support of the body is better in the latter type of locomotion [6]. In this 
regard, the possibility of quadrupedalism appearing as an epiphenomenon secondary to very 
early onset balance problem cannot be ruled out. The Indian cases were noted to have mild 
forms of limb dystonia, which became obvious when they attempted bipedal locomotion. In 
one of his reviews, Uner Tan pointed out that basal ganglia signs were absent [7]. Future stud‐
ies in UTS may need to incorporate these clinical features to revise our present understanding 
of this interesting syndrome.
In summary, the clinical observations made in the Indian cases of UTS suggest that  components 
of limb dystonia may be part of the clinical presentation of the syndrome.
3. Sepiapterin reductase deficiency, a rare but treatable paediatric 
movement disorder
Dopa responsive dystonias (DRDs) are a genetically heterogeneous subgroup of paediatric 
neurotransmitter diseases (PNDs), which occur due to defective tetrahydrobiopterin (BH4) 
metabolism. Since hyperphenylalaninemia, which is a useful marker in the screening of such 
diseases, is not always present, the disorders are classified based on the presence or absence of 
hyperphenylalaninemia. BH4 defects without hyperphenylalaninemia include dopa respon‐
sive dystonia (Segawa disease), sepiapterin reductase deficiency (SRD) and dihydrobiopterin 
reductase deficiency. BH4 defects without hyperphenylalaninemia include autosomal reces‐
sive GTP‐1 cytohydroxylase deficiency, 6‐pyruvoyl‐teytrahydropterin synthase deficiency 
(6‐PTS) and dihydropteridine reductase deficiency without hyperphenylalaninemia. In addi‐
tion primary defects of monoamine synthesis include Tyrosine hydroxylase deficiency (TH) 
and Aromatic l‐amino acid decarboxylase deficiency (AADC).
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Examples of autosomal dominant and recessive types of dopa responsive dystonias are 
described. Segawa disease with autosomal dominant inheritance is a landmark in this group 
of diseases. Sepiapterin reductase deficiency (SRD) is a rare example of autosomal recessive 
variety [8]. It is caused by mutation in the SPR gene, located on the chromosome 2p14‐p12 [9]. 
The clinical presentation includes cognitive delay along with dopa responsive mixed motor 
disorder often masquerading as cerebral palsy [10]. Neonatal screening tests are not helpful 
in the diagnosis of this disease since it is not associated with hyperphenylalaninemia. 
However the presence of certain additional clinical features like oculogyric crisis, diurnal 
fluctuation of the symptoms and hypersomnia provide a clue to the clinical suspicion. Clinical 
response to dopamine therapy is often rewarding and at times dramatic. The laboratory diag‐
nosis of SRD is based on CSF analysis of neurotransmitter metabolites and pterins. The clas‐
sical CSF findings in SRD include increased levels of sepiapterin along with reduced levels of 
5‐hydroxyindolacetic acid and homovanillic acid. The diagnosis can be confirmed by study‐
ing the SR activity in the fibroblasts and mutational analysis of the SPR gene.
The following paragraphs provide an overview of the clinical profile of SRD based on the 
information obtained from various case reports and recent reviews [11, 12] of Indian cases 
have been summarized.
3.1. Demography
Till date, a total number of 43 cases have been recognized from all over the world and are 
reviewed by Friedman et al. [11]. These include cases which are published and those docu‐
mented in the international database maintained by the PND society. Both genders are equally 
represented. The cases belong to a wide ethnic background from various countries including 
India. A founder effect was suspected in the seven patients reported from Malta.
3.2. Clinical profile
3.2.1. Mixed motor signs and symptom
SRD causes symptoms related to dopamine and serotonin metabolism disturbances. The 
salient clinical features include motor and language delay associated with axial hypotonia, 
limb weakness, dystonia with diurnal fluctuation and oculogyric crisis. The latter group of 
symptoms often show sleep benefit. Other symptoms include parkinsonism, limb hypotonia, 
hypertonia and dysarthria. As against Segawa disease, the occurrence of dystonia is not uni‐
versal in SRD. It is present in only about half of the cases. Less common neurological features 
include chorea, myoclonus and seizures.
The symptoms of SRD usually appear in age‐related pattern [12]. The symptoms of axial 
hypotonia, tremors, hypersomnia, oculogyric crisis and sleep benefit usually appear in the 
first year of life while limb spasticity, diurnal fluctuation, dysarthria and dystonia become 
obvious between the ages of 2 and 6 years. The triad of oculogyric crisis, paroxysmal stiffen‐
ing and axial hypotonia may be considered as a strong clue to suspect the diagnosis of SRD 
in the infantile group. However, these symptoms may persist or appear during late child‐
hood as well. It is not unusual for the paroxysmal episodes to be misdiagnosed as seizure 
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 phenomenon resulting in delayed diagnosis and unwanted use of anticonvulsants. ‘Cerebral 
palsy’ is the commonest diagnosis in majority of the cases before reaching a final diagnosis.
3.2.2. Non‐motor neurological features
These include sleep disturbances, behavioural changes and cognitive disabilities. Hypersomnia 
is the commonest sleep disturbance and present in nearly 50% cases especially in the infantile 
age group. Behavioural changes are also seen in slightly more than half of the cases. Cognitive 
disabilities of varying degree are seen in almost 90% cases. Nearly half of them have mental 
retardation, whereas others have mild‐to‐moderate disability.
3.2.3. Other features
Non‐specific non‐neurological features have been reported in SRD. These include pulmonary 
symptoms, vegetative symptoms such as gastrointestinal disturbances, hyperhidrosis, pre‐
mature greying of hairs and menstrual abnormalities.
3.2.4. Salient investigations
CSF analysis is the mainstay of the diagnosis of SRD. The classical findings include
i) Low 5‐hydroxyindolacetic acid and homovanillic acid levels.
ii) Elevated total biopterin, dihydrobiopterin and sepiapterin.
The study of SR activity in the fibroblast cultures has been performed in few cases and found 
to be confirmative. SR activity is either less or absent in such cases.
Genotyping of the documented 42 cases has revealed 16 mutations in the SPR gene. The 
intronic homozygous variant c596‐2A>G is the most common genotype.
3.2.5. Treatment responses and outcomes
Substitution therapy is the mainstay of treatment in SRD. Most cases were treated either 
with l‐dopa/carbidopa or benserazide (doses ranging from 1.45 mg to 20 mgm/kg/day) or 
5‐hydroxytryptophan (doses ranging from 0.65 to 5.9 mgm/kg/day). Combination therapy 
is also useful and in some cases better than the use of single drug. Other drugs used to treat 
include BH4, bromocriptine, anticholinergics, selegiline, sertraline and melatonin.
The response to treatment is always rewarding and at times dramatic. Patients may show 
improvement in motor activity and sleep disturbances within few hours of administering 
medication. Children who have been chair‐bound or bed‐bound may start moving and enjoy 
the unexpected relief with tremendous excitement. The rapid recovery is usually associated 
with appearance of choreiform dyskinesias requiring dose titration. Few cases show par‐
tial improvement. Favourable response to treatment is noted even in those cases who have 
received the treatment late in the course of their illness due to delayed diagnosis. Long‐term 
follow‐up has shown that few cases may require mild escalation in the dose of the drugs to 
maintain the favourable benefit. It also shows that response to therapy is not as complete as 
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seen in Segawa disease. Residual motor and cognitive dysfunction may persist. Early treat‐
ment is associated with better recovery.
3.2.6. Indian cases of SRD
Five Indian cases (three males and two females) of chemically and genetically proven SRD 
have been documented in the international database maintained by the PND society (BIODEF 
database IDs # 526,527,637,638 and 639) [13]. All of these cases have been reported from the 
Belgaum region of North Karnataka [11, 14]. These cases with consanguineous parenthood 
belonged to two independent families. The referring diagnosis in all these cases was ‘cerebral 
palsy’. All cases showed very favourable and sustained response to l‐dopa therapy (Figure 3). 
They have been followed up clinically for the past 5 years. The average maintenance dose of 
l‐dopa was 1.5–2 mg/kg body weight in all these cases. All cases had the core symptom complex 
inclusive of psychomotor delay, axial hypotonia, limb hypotonia/hypertonia, acral dystonia/
athetosis, diurnal variation and sleep benefit. Table 1 summarises the clinical data which was 
present in addition to this core symptom complex.
Figure 3. This figure reveals the clinical state of the patient (BIODEF #523) of SRD before and after administration of 
levodopa. The left half of the figure shows evidence of truncal hypotonia and spastic‐dystonia limb posturing. The right 
half of the figure shows the clinical state of the patient after administration of a single low dose of levodopa/carbidopa. 
The response was dramatic and seen within 12 hours.
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It is likely that SRD is more common all over the world but possibly remains under‐diagnosed 
due to lack of awareness and inadequate laboratory services. Such cases are likely to masquer‐
ade as ‘cerebral palsy’ and remain untreated for life.
4. Hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) is an untreatable rare genetic disorder, which causes 
long‐term physical disability in the affected individuals. There is a high degree of genetic het‐
erogeneity with over 60 causative genes identified so far. A collaborative study using whole 
genome sequencing (WSG) was performed in 10 HSP families from Belgaum in Karnataka, 
India. Pathogenic variants were identified in four consanguineous families. This included a 
novel frameshift homozygous deletion in CYP2U1 (c.782_785delTCTG) gene in one family 
and a novel homozygous donor splice site variant in DDHD2 (c.1125+1G>T) gene in another 
family. A probable genetic cause was identified in 40% of the families limited to consanguine‐
ous families in whom a family study was possible. Mutations were found in genes causing 
metabolic disorders such as Zellweger spectrum disorder and GM1 gangliosidosis. This study 
supports a role of WGS as a diagnostic tool in HSP [15].
Case no.
sex
Onset age Age at diagnosis Features additional 
to core symptom 
complex
Response to 
l‐dopa/carbidopa 
therapy
5‐year follow‐up
1. Male 3 months 10 years Premature greying 
of hairs/wheezing
Dramatic and well 
sustained to date
Independent, 
attends school 
and plays football
2. Female 3 months 11 months Wheezing Dramatic and well 
sustained to date
Independent, 
attends school 
and games
3. Male 9 months 5 years Two episodes of 
seizures
Improvement noted 
after a week of 
initiating l‐dopa 
therapy. Well‐
sustained to date
Independent. 
Attends school 
and regular 
games
4. Male 3 months 3 years Irritable behaviour/
bilateral talipes 
equinovarus
Improvement noted 
after 1 week of 
initiating l‐dopa 
therapy. Well‐
sustained to date
Independent 
and attends 
school. Scholastic 
performance is 
average
5. Female 3 months 1 year Irritable behaviour 
with incessant 
crying/bilateral 
talipes equinovarus
Improvement noted 
after 1 week of 
initiating l‐dopa 
therapy. Well‐
sustained to date
Stands and 
walks few steps 
independently.
Does not attend 
school. Irritable 
behaviour
Table 1. Clinical summary of Indian cases of SRD.
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4.1. Stem cell modelling of HSP
HSP is characterised by degeneration of long axons along the corticospinal tract, leading to 
lower limb spasticity. The mechanisms underlying HSP mutations that lead to degeneration 
of the long axons are unclear. Researchers have recently used patient‐derived cells from the 
olfactory mucosa, a population of neural progenitor cells, derived from biopsies of the olfac‐
tory mucosa from HSP patients with SPAST mutations and from healthy controls, in order to 
identify cell functions altered in HSP [16]. Mutations in the SPAST gene account for the largest 
group of adult‐onset HSP patients. These researchers show that SPAST patient‐derived cells 
have reduced expression of protein Spastin (encoded by SPAST), reduced expression of stabi‐
lized microtubules, alterations in transport of cellular cargo and increased oxidative stress [17] 
(Figure 4). Based on their findings, Gautam Wali and colleagues propose that the downstream 
effects of SPAST mutations may cause a chronic state of oxidative stress in cortical motor neu‐
rons and other neurons, which ultimately leads to their degeneration, eventually manifesting 
the disease. They also show that the defects observed in the patient cells can be rescued using 
a microtubule‐binding drug, Epothilone D. Epothilone D can cross the blood‐brain barrier, 
making it a potential drug for HSP therapy [18].
Figure 4. This figure summarises the mechanism of cell organelle dysfunction in HSP as confirmed by Gautam Wali 
and colleagues using patient‐derived olfactory stem cells. They suggest a mechanism whereby SPAST mutations lead 
to reduced levels of stable microtubules which compromises cargo trafficking and leads to increased oxidative stress. 
These downstream effects of SPAST mutations may cause a chronic state of oxidative stress in cortical motor neurons 
and other neurons, which ultimately leads to their degeneration, eventually manifesting the disease. They also showed 
that Epothilone D, a microtubule‐binding drug, can rescue the cell function defects in patient cells, making it a potential 
candidate for a future therapy for HSP.
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